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Purpose: To assess the prevalence and risk factors of microalbuminuria in nondiabetic 
hypertensive patients in Thailand.
Patients and methods: A cross-sectional study was performed during January to December 
2007 at outpatients departments of Bhumibol Adulyadej hospital. Nondiabetic hypertensive patients 
without a history of pre-existing kidney diseases participated in this study. A questionnaire was 
used for collecting information on demographics, lifestyle, and family history of cardiovascular 
and kidney disease. Spot morning urine samples were collected for albuminuria estimation. Albu-
minuria thresholds were evaluated and defined using albumin-creatinine ratio (ACR).
Results: A total of 559 hypertensive patients (283 males, 276 females), aged 58.0 ± 11.6 years 
were enrolled in this study. Microalbuminuria (ACR 17 to 299 mg/g in males and 25 to 299 mg/g 
in females) was found in 93 cases (16.6%) [15.0%‑18.2%]. The independent determinants of 
elevated urinary albumin excretion in a multiple logistic regression model were; body mass 
index 30 (odds ratio (OR) = 2.24, 95% confidence intervals (CI): 1.33–3.76) and dihydropyri-
dine calcium channel blockers (DCCB) use (OR = 1.92, 95% CI: 1.22‑3.02).
Conclusion: In Thai nondiabetic hypertensive patients, microalbuminuria was not uncommon. 
Obesity and use of dihydropyridine calcium channel blocker were found to be the important 
predictors. Prognostic value of the occurrence of microalbuminuria in this population remains 
to be determined in prospective cohort studies.
Keywords: microalbuminuria, hypertension, obesity, calcium channel blocker, metabolic 
syndrome
Introduction
Microalbuminuria has been shown to be associated with an increased risk of 
  cardiovascular1,2 and progressive kidney disease3–6 not only in diabetes but also in 
nondiabetic subjects. In addition, treatment aimed to reduce albuminuria levels have 
been shown to reduce the risk for cardiovascular events7 as well as kidney disease 
progression.8 In hypertensive subjects, microalbuminuria has now been considered 
as an essential component in the assessment of subclinical organ damage because 
its detection is easy and relatively inexpensive.9 In Thailand, however, reliable data 
about epidemiology of microalbuminuria in nondiabetic hypertensive patients and 
its association with cardiovascular and renal morbidity are limited. Previous study 
by Buranakitjaroen et al, included 505 Thai hypertensive subjects who attended the 
hypertension clinic at Siriraj Hospital, had reported the prevalence of microalbu-
minuria and its associated factors.10 However, the population in this study was the 
patients who were cared for by hypertensive specialists and might not represent the Vascular Health and Risk Management 2010:6 158
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whole hypertensive population of Thailand. Furthermore, 
the diagnostic test from this study was based on antibody-
based dipstick rather than quantitative measuring of albu-
minuria. The aim of our study, therefore, was to assess the 
prevalence of microalbuminuria in hypertensive patients 
who attend general medical clinics. The screening method 
was antibody-based dipstick, but these were confirmed by 
urinary albumin creatinine ratio (ACR) in subjects who 
had tested positive with primary screening. The results 
from this study will provide us with a precise prevalence 
of microalbuminuria as well as associated factors and could 
demonstrate a value of screening for microalbuminuria in 
this population.
Material and methods
Study population
A cross-sectional study was performed from January to 
December 2007 at 3 out-patient departments of director-
ate of medical services, Royal Thai Air Force including: 
(1) Department of preventive medicine, (2) Department 
of medicine, Bhumibol Adulyadej hospital, and (3) Pri-
mary care unit, Bhumibol Adulyadej hospital. Nondiabetic 
hypertensive patients, age 18 years, without a history of 
pre-existing kidney diseases participated in this study. The 
major inclusion criteria were patients with hypertension 
(defined by sitting blood pressure (BP) 140/90 mmHg 
in those not previously diagnosed with hypertension or 
those who were previously diagnosed with hypertension 
and reported current use of antihypertensive medications). 
Exclusion criteria were those with previously diagnosed 
diabetes mellitus or fasting blood glucose 126 mg/dL, 
impaired kidney function (serum creatinine 1.4 mg/dL in 
male, or 1.2 mg/dL in female), or history associated with 
false positive albuminuria (fever, menstruation, urinary tract 
infection and post exercise). All participants gave written 
informed consent. This study was approved by Bhumibol 
Adulyadej hospital ethics committee.
Data collection and evaluation
The two page questionnaire was used for collecting information 
on demographics, lifestyle, current medical illness, and 
  family history of cardiovascular and kidney disease. 
Duration of hypertension and data about antihypertensive 
medications were collected from medical records. All 
  participants have their BP measured after a 5 minutes rest 
with a calibrated digital BP monitor. Systolic and diastolic 
BP measurements were calculated as the mean of the last two 
visits. Participants were also measured for weight, height, 
and waist circumference. Data about blood chemistry (fasting 
plasma glucose (FPG), creatinine (Cr), triglyceride (TG), 
total cholesterol (TC), high-density lipoprotein cholesterol 
(HDL-c), and uric acid (UA)) were collected from medical 
record within last 6 months.
Glomerular filtration rate (GFR) was estimated from 
the Modification of Diet in Renal Disease (MDRD) study 
equation as follows:11
Estimated GFR (mL/min/1.73 m2) =   186.3*(serum creatinine 
by Jaffe)‑1.154*age‑0.203
  (*0.742 for woman).
Definitions
Obesity and overweight were defined according to World 
Health Organization (WHO) guidelines.12 Subjects were 
  classified as having impaired fasting glucose if fasting 
glucose 100 mg/dL.13 Metabolic syndrome was defined 
according to the International Diabetes Federation (IDF) 
worldwide definition of metabolic syndrome (IDF 2005 
guidelines)14 that requires the presence of abdominal obesity 
according to ethnic-specific cutoff waist circumference 
(waist circumferences 90 cm. for men, or 80 cm. for 
women) plus any two or more of the following: (1) high TG 
(TG  150 mg/dL or treatment for this abnormality), (2) low 
HDL-c (HDL-c  40 mg/dL in male subjects and 50 mg/dL 
in female subjects or treatment for this abnormality), (3) high 
BP (systolic BP  130 or diastolic BP  85 mmHg or treat-
ment of hypertension), (4) high fasting glucose (FPG  
100 mg/dL or previously diagnosed type 2 diabetes). High 
serum uric acid was defined as serum uric acid 8.0 mg/dL 
for men, and 7.0 mg/dL for women. High cholesterol 
was defined as taking cholesterol lowering medications, or 
serum cholesterol 240 mg/dL. Subjects were classified 
as smokers if they reported smoking or having smoked 
cigarettes during the previous 5 years. A family history of 
cardiovascular disease and kidney disease was considered 
present if at least one first degree relative had documented 
the diseases.
Urinary albumin measurements
All participants gave a spot morning urine sample for 
  analysis. Screening for elevated urinary albumin excretion 
(UAE) was tested by antibody-based dipstick: Micral test 
strips (Roche Diagnostics, Basel, Switzerland) and reported 
as negative or positive (at least 20 mg/L). Urine sample from 
participants who report positive from Micral test will be 
sent for quantitative measurement for albuminuria by using Vascular Health and Risk Management 2010:6 159
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ACR. Albuminuria measured as urine albumin concentration 
(UAC) by the method of immunoturbidimetric technique 
with MODULAR ANALYTICS P 800 module analyzer 
(Roche Diagnostics, Mannheim, USA). Urine creatinine 
was measured using the modified Kinetic Jaffé (KJ) method 
using the same analyzer for albumin. Elevated UAE was 
defined if ACR was more than 17 mg/g creatinine in males 
and 25 mg/g creatinine in female as per standard guideline.15 
  Microalbuminuria was defined as ACR more than gender 
specific cutoff levels but less than 300 mg/g creatinine. 
Macroalbuminuria was defined as ACR more than 300 mg/g 
creatinine.
Statistical analysis
An overall prevalence and specific population prevalence 
of microalbuminuria were estimated along with their 
95% confidence interval (CI). Categorical variables were 
  summarized using frequency and percentages ± standard 
error (SE) while continuous variables were summarized 
using mean ± standard deviations (SD) unless otherwise 
indicated. Descriptive statistics were used to compare 
the presence of elevated UAE with comparisons evalu-
ated using t-tests for continuous variables and chi-square 
tests for categorical variables. The relationship between 
an elevation of UAE and covariates were assessed using 
a simple logistic regression model and reported as crude 
odds ratios (OR) with 95% confident intervals (CI). Mul-
tiple logistic regression was then used to examine if the 
presence of elevated UAE was associated with obesity 
(BMI  30), metabolic syndrome, abdominal obesity, high 
blood pressure (BP  130/85 mmHg), and the usage of 
calcium channel blockade medication. Results are presented 
as adjusted ORs with upper and lower 95% CIs. P values 
were two sided, and P  0.05 was considered to indicate 
statistical significance. All analyses were performed using 
SPSS statistical package version 15.0 (SPSS Inc, Chicago, 
IL, USA).
Results
Demographic and clinical characteristics
A total of 559 hypertensive patients, aged 58.0 ± 11.6 years 
were enrolled in this study. Demographic and baseline clini-
cal characteristics of studied subjects were shown in Tables 1 
and 2 respectively. Two hundred and eighty three were males 
and 276 were females. The mean duration of hypertension 
was 60.3 ± 58.3 months. Mean body mass index (BMI) was 
26.1 ± 6.9 kg/m2 with ninety-seven patients (17.4%) were 
found to be obesity (BMI  30 kg/m2). Mean BMI of patients 
in the macroalbuminuria and microalbuminuria groups were 
significantly higher than those in the normoalbuminuria 
group (P = 0.04 and P = 0.03, respectively). Mean estimated 
GFR in males and females were 77.7 ± 16.8 mL/min/1.73 m2 
and 80.8 ± 19.2 mL/min/1.73 m2, respectively. Majority of 
  subjects were not currently smokers (89.8.1%). Underlying 
disease was also described. Prevalence of metabolic syn-
drome was about 41.3% whereas the prevalence of high 
cholesterol and impaired fasting glucose (IFG) were as high 
as 59.9% and 36.8%. However, history of cardiovascular 
disease and cerebrovascular disease (CVA) were quite rare, 
ie, 5.6%, and 3.2%, respectively. Family history of cardio-
vascular disease and kidney disease were found in 10.5% 
and 6.6%.
Table 1 Demographic data of study subjects
Characteristics Number  
n = 559
Percent ± SE
Age, year, mean ± SD 58.0 ± 11.6
Gender  
  Male 
  Female
 
283  
276
 
50.6 ± 2.1 
49.4 ± 2.1
Site   1 Preventive medicine 
2 Medicine 
3 Primary care unit
169  
276  
114
30.2 ± 1.9 
49.4 ± 2.1 
20.4 ± 1.7
Region of origin (n = 552)  
  Bangkok  
  Central 
  Northern  
  North-eastern 
  Eastern  
  Southern
 
207  
218  
41  
40  
31 
15
 
37 ± 2.0 
39 ± 2.0 
7.3 ± 1.1 
7.2 ± 1.1 
5.5 ± 1.0 
2.7 ± 0.6
Educational level (n = 532)  
  High school  
  University 
  Post-graduate
 
432  
94 
6
 
81.2 ± 1.7 
17.7 ± 1.6 
1.1 ± 0.4
Cardiovascular disease (n = 556) 
  Yes 
  No
 
31  
525
 
5.6 ± 1.0 
94.4 ± 1.0
Cerebrovascular disease (n = 556)  
  Yes 
  No
 
18  
538
 
3.2 ± 0.7 
96.8 ± 0.7
Family history of CVD (n = 514)  
  Yes 
  No
 
54 
460
 
10.5 ± 1.4 
89.5 ± 1.4
Family history of CKD (n = 514) 
  Yes 
  No
 
34 
480
 
6.6 ± 1.1 
93.4 ± 1.1
Smoking (n = 537) 
  Yes 
  No
 
57 
480
 
10.6 ± 1.3 
89.4 ± 1.3
Abbreviations: CVD, cardiovascular disease; CKD, chronic kidney disease.Vascular Health and Risk Management 2010:6 160
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Blood pressure control and 
antihypertensive medication
Table 3 shows the extent of BP control achieved in 
study subjects. There were 306 (47.2%) patients whose 
systolic BP and diastolic BP were both well con-
trolled(140/90 mmHg), while normalization rates 
of either systolic BP (140 mmHg) or diastolic BP 
(90 mmHg) were 50.8% and 77.6%, respectively. The 
presence of poorly controlled BP was seen more frequently 
in subjects with increased levels of albuminuria (Table 2). 
The mean number of antihypertensive agents was 1.64 ± 
0.98 and 54.9% of subjects were prescribed with combina-
tion therapy. Dihydropyridine calcium channel blockers 
(DCCB) were prescribed in 36.5% of patients, followed 
by a thiazide type diuretic (34.3%) and ACE-I (33.3%). 
Antihypertensive medications in study subjects according 
to albuminuria are shown in Table 4. Patients who were 
prescribed with DCCB have a significantly higher percent-
age of having microalbuminuria and macroalbuminuria 
compared with other classes of drugs.
Prevalence of microalbuminuria
Overall, the frequency of an elevated UAE by antibody-
based dipstick of 559 screened population was 183 (32.7%). 
However, 110 subjects who were test positive by anti-
body-based dipstick were confirmed by increased albu-
min-creatine ratio, giving a prevalence of 19.6% (95% 
CI: 14.4%‑18.8%). After excluding 17 persons with 
  macroalbuminuria, microalbuminuria was found in 93 cases 
(16.6%) [15.0%‑18.2%]. The prevalence was similar in 
males and females, ie 16.6% (95% CI: 14.4%‑18.8%) and 
16.7% (95% CI: 14.4%‑18.9%), respectively. The gender-
specific prevalences of albuminuria are shown in Table 5.
Factors associated with elevated 
urinary albumin excretion
Microalbuminuria and macroalbuminuria were combined 
and compared with the normoalbuminuria group for this 
analysis. Odds of having elevated UAE was estimated 
for those 13 factors (ie, age, sex, smoking status, BMI, 
waist circumference, duration of hypertension, BP control, 
Table 2 Clinical characteristics of study subjects
Characteristics All  
(n = 559)
Normo-albuminuria  
(n = 449)
Micro-albuminuria  
(n = 93)
Macro-albuminuria   
(n = 17)
Age (years) 58.0 ± 11.6 58.2 ± 11.0 57.3 ± 13.7 55.5 ± 15.4
Male gender (%) 50.6 ± 2.1 51.2 ± 2.4 50.5 ± 5.2 35.3 ± 11.6
Weight (kg) 67.2 ± 13.7 66.6 ± 13.4 69.4 ± 14.8 69.2 ± 16.1
BMI (kg/m2) 26.1 ± 6.9 25.9 ± 7.2 26.9 ± 5.1 28.0 ± 5.9
Obesity (%) 17.4 ± 1.6 14.3 ± 1.7 26.9 ± 4.6* 47.1 ± 12.1**
Smoker (%) 10.2 ± 1.2 9.4 ± 1.4 16.1 ± 3.8 0
Systolic BP (mmHg) 140.6 ± 16.3 139.0 ± 15.2 147.1 ± 19.1** 148.5 ± 15.8*
Diastolic BP (mmHg) 80.9 ± 11.4 80.4 ± 11.4 82.9 ± 11.0 84.3 ± 10.9
Duration of HT (months) 60.3 ± 58.3 57.3 ± 55.7 70.9 ± 63.4 80.1 ± 83.6
FPG (mg/dL) 99.1 ± 24.1 97.4 ± 14.7 106.7 ± 48.2* 103.5 ± 12.0
IFG (%) 36.8 ± 2.1 34.9 ± 2.3 48.2 ± 5.2 56.3 ± 12.4
eGFR (ml/min/1.73 m2) 79.3 ± 17.8 79.1 ± 16.7 79.4 ± 21.2 86.3 ± 23.0
Uric acid (mg/dL) 6.3 ± 3.0 6.4 ± 3.3 6.2 ± 1.6 6.4 ± 1.7
Total cholesterol (mg/dL) 198.7 ± 39.5 198.5 ± 39.4 198.1 ± 40.7 206.2 ± 39.3
High cholesterol (%) 59.9 ± 2.1 59.4 ± 2.3 58.1 ± 5.1 82.4 ± 9.2
Triglyceride (mg/dL) 144.5 ± 97.4 141.2 ± 102.4 158.6 ± 69.7 153.8 ± 88.2
HDL-c (mg/dL) 57.1 ± 15.0 57.6 ± 15.3 55.1 ± 13.7 56.3 ± 14.4
Uncontrolled BP (%) 52.8 ± 2.1 49.2 ± 2.4 66.7 ± 4.9* 70.6 ± 11.0
Number of antihypertensive  
drug used
1.64 ± 0.98 1.62 ± 0.97 1.7 ± 0.98 1.94 ± 1.03
METS-IDF (%) 41.3 ± 2.1 38.1 ± 2.3 54.8 ± 5.2* 52.9 ± 12.1
Abbreviations: BMI, body mass index; BP, blood pressure; HT, hypertension; FPG, fasting plasma glucose; IFG, impaired fasting glucose; eGFR, estimated glomerular filtration 
rate; HDL-c, high density lipoprotein cholesterol; METS-IDF, metabolic syndrome by IDF criteria.
**P  0.005, *P  0.05 compared with normoalbuminuria group.Vascular Health and Risk Management 2010:6 161
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  metabolic syndrome, FPG, cholesterol, triglyceride, HDL, 
and uric acid) that were suspected to be associated with 
elevated UAE (Table 6). In addition, data about current 
medication use (ie, renin angiotensin system (RAS) blockade, 
DCCB, number of antihypertensive medications, and statin) 
were also assessed. In univariate analysis, elevated UAE was 
associated with increased BMI, abdominal obesity, poor 
blood pressure control, metabolic syndrome, and the using 
of DCCB. These 5 factors were therefore considered simul-
taneously in the multivariated logistic model. After adjust-
ing for confounding effects, the independent determinants 
of elevated UAE were; body mass index 30 (OR = 2.24, 
95% CI: 1.33‑3.76) and DCCB use (OR = 1.92, 95% CI: 
1.22–3.02). Subjects who had metabolic syndrome were 
about 20% higher risk (OR = 1.2, 95% CI: 1.0‑1.4) of having 
elevated UAE than subjects who did not. However, this risk 
was only borderline significant.
Discussion
Microalbuminuria is common in Thai nondiabetic hyperten-
sive patients with a prevalence of 16.6% and independently 
associated with obesity and certain classes of antihyperten-
sive medication. A number of previous studies evaluated 
the prevalence of microalbuminuria in hypertensive patients 
has been published, which is varied from 16% in the USA,16 
11.5% to 30% in Europe,17–21 and 14.4 to 26.2% in Asian 
populations.22–24 This varying might be due to type of 
study-base (ie, community versus hospital-base), patient 
Table 3 Antihypertensive medications used by study subjects categorized by blood pressure control
Antihypertensive  
medication
140/90 mmHg  
(n = 264)
140/90 mmHg  
(n = 105)
140/90 mmHg  
(n = 170)
140/90  
mmHg  
(n = 20)
Total (n = 559) 264 (47.2%) 105 (18.8%) 170 (30.4%) 20 (3.6%)
ACE-I (n = 186, 33.3%) 86 (32.6%) 32 (30.5%) 62 (36.5%) 6 (30.0%)
ARB (n = 137, 24.5%) 50 (18.9%) 35 (33.3%)* 48 (28.2%)* 4 (20.0%)
Thiazide (n = 192, 34.3%) 92 (34.8%) 37 (35.2%) 56 (32.9%) 7 (35.0%)
DCCB (n = 204, 36.5%) 88 (33.3%) 44 (41.9%) 66 (38.8%) 6 (30.0%)
β-Blocker (n = 178, 31.8%) 81 (30.7%) 27 (25.7%) 65 (38.2%) 5 (25.0%)
On 0–1 class of drugs (n = 252, 45.1%) 128 (48.5%) 45 (42.9%) 68 (40.0%) 11 (55.0%)
On 2 classes of drugs (n = 204, 36.3%) 93 (35.2%) 42 (40.0%) 61 (35.9%) 8 (40.0%)
On = 3 classes of drugs (n = 103, 18.6%) 43 (16.3%) 18 (17.1%) 41 (24.1%)* 1 (5.0%)
Abbreviations: ACE-I, angiotensin converting enzyme-inhibitor; ARB, angiotensin receptor blocker; DCCB, dihydropyridine calcium channel blocker.
Table 4 Antihypertensive medications used by study subjects according to albuminuria levels
All  
(n = 559)
Normo-albuminuria  
(n = 449)
Micro-albuminuria  
(n = 93)
Macro-albuminuria   
(n = 17)
ACE-I 186 (33.3%) 142 (31.6%) 35 (37.6%) 9 (52.9%)
ARB 137 (24.5%) 116 (25.8%) 19 (20.4%) 2 (11.8%)
DCCB 204 (36.5%) 147 (32.7%) 46 (49.5%)* 11 (64.7%)*
NDCCB 8 (1.4%) 7 (1.6%) 1 (1.1%) 0 (0%)
Thiazide diuretics 192 (34.3%) 164 (36.5%) 25 (59.5%) 5 (29.4%)
Loop diuretics 10 (1.8%) 7 (1.6%) 3 (3.2%) 0 (0%)
β-Blocker 178 (31.8%) 141 (31.4%) 31 (33.3%) 6 (35.3%)
On 0–1 class of drugs 252 (45.1%) 204 (45.4%) 43 (46.2%) 5 (29.4%)
On 2 classes of drugs 204 (36.3%) 168 (37.4%) 30 (32.3%) 6 (35.3%)
On =3 classes of drugs 103 (18.6%) 77 (17.1%) 20 (21.5%) 6 (35.3%)
Abbreviations: ACE-I, angiotensin converting enzyme-inhibitor;  ARB, angiotensin receptor blocker; DCCB, dihydropyridine calcium channel blocker; NDCCB,   
nondihydropyridine calcium channel blocker.
*P  0.05 compared with other classes.Vascular Health and Risk Management 2010:6 162
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characteristics, urine sample collection, and the methods of 
tests used. In Thailand, a study at Siriraj hospital had reported 
a prevalence of microalbuminuria, assessed by antibody-
based dipstick, of 18.6% comparable to our study.10 However, 
it should be kept in mind that prevalence of microalbuminuria 
by dipstick screening in our study was 32.7% using the same 
cut off value at 20 mg/L. There had been a study showing 
that screening of microalbuminuria by Micral test strips 
had a low positive predictive value of 69%.25 Therefore, we 
could say that our population had much higher prevalence 
of microalbuminuria. These results could be explained by 
a difference in population characteristics as following: (1) 
patients enrolled in Siriraj study were from a hypertension 
clinic and cared for by a hypertensive specialists; (2) 
majority of patients taken on combination antihypertensive 
medication with a mean number of 2.6 ± 0.8; and (3) higher 
BP normalization rate (BP  140/90 78.8% compared with 
47.2%). Better BP control could explain the lower prevalence 
of target organ damage.
Various studies have documented risk factors associated 
with microalbuminuria. Among those factors, obesity has 
been shown to be important in many studies.26–29 To the 
best of our knowledge, this is the first study to show that 
increased urinary albumin excretion is associated with 
  obesity in the Thai population. The importance of obe-
sity in the development of albuminuria has been studied 
in experimental models. It was shown that obesity, by 
  several mechanisms, can lead to glomerular hyperfiltration 
and subsequently developed early histological changes 
together with the development of albuminuria.30 Recent 
Table 5 Prevalence of albuminuria according to gender
Gender n Normoalbuminuria Microalbuminuria Macroalbuminuria
n Prevalence (%) n Prevalence (%) n Prevalence (%)
Male 283 230 81.3 ± 2.3 47 16.6 ± 2.2 6 2.1 ± 0.8
Female 276 219 79.3 ± 2.4 46 16.7 ± 2.2 11 4.0 ± 0.8
Overall 559 449 80.3 ± 1.7 93 16.6 ± 1.6 17 3.0 ± 0.7
Table 6 Odds ratio and 95% confidence interval for presence of elevated urinary albumin excretion: univariate and multivariate 
  analyses
Variables Univariate 95% CI P-value Multivariate 95% CI P-value
BMI  30 kg/m2 2.58 1.59–4.19 0.001 2.24 1.33–3.76 0.002
DCCB 2.20 1.44–3.36 0.001 1.92 1.22–3.02 0.005
METS-IDF 1.95 1.28–2.97   0.002 1.65 1.02–2.67 0.043
Abdominal obesity-Asia 1.78 1.06–2.99   0.028 1.63 0.95–2.80 0.077
BP  130/85 mmHg 1.84 1.05–3.22   0.033 1.49 0.83–2.67 0.182
Age  60 years 0.85 0.55–1.29   0.444
Female gender 1.13 0.74–1.71   0.567
Smoking 1.57 0.83–2.96   0.163
HT  10 years 1.77 1.10–2.85   0.019
FPG  100 mg/dL 1.49 0.96–2.29   0.073
TG  150 mg/dL 1.42 0.92–2.18   0.110
Low HDL-c 1.38 0.82–2.33   0.229
High uric acid 1.36 0.84–2.20   0.217
High Cholesterol 1.02 0.56–1.85   0.951
ACE-I or ARB 0.97 0.64–1.48   0.895
Anti HT  3 classes 1.48 0.90–2.46   0.125
Statins 1.18 0.78–1.80   0.437
Abbreviations: BMI, body mass index; DCCB, dihydropyridine calcium channel blocker; METS-IDF, metabolic syndrome by IDF criteria; BP, blood pressure; HT, hypertension; 
FPG, fasting plasma glucose; TG, triglyceride; HDL-c, high density lipoprotein cholesterol; ACE-I, angiotensin converting enzyme-inhibitor; ARB, angiotensin receptor 
blocker.Vascular Health and Risk Management 2010:6 163
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studies by Goumenos et al demonstrated histological 
lesions such as glomerulomegaly as well as focal segmental 
  glomeruloscerosis in patients with morbid obesity even 
before the appearance of microalbuminuria.31 Furthermore, 
microalbuminuria in nondiabetic subjects might be part 
of insulin resistance syndrome.32,33 Many risk factors 
  associated with microalbuminuria (eg, hypertension, 
hyperglycemia, obesity, hyperlipidemia) are well-known 
components of insulin resistance syndrome (metabolic 
  syndrome). Therefore, one could argue that insulin 
resistance is the key pathophysiologic mechanism to 
link between all of the above-mentioned risk factors and 
microalbuminuria.34 Nevertheless, results from our study 
showed only a borderline association between albuminuria 
and metabolic syndrome. This finding is similar to a study 
by Kitiyakara et al showing that metabolic syndrome was 
not associated with developing chronic kidney disease in 
the Thai population when using IDF definition with Asian-
specific cutoff waist circumference.35
Another finding from this study is the association 
between certain classes of antihypertensive medication and 
urinary albumin excretion. In our study, patients currently 
taking DCCB had a higher prevalence of microalbuminria 
compared with other classes. This relation was indepen-
dent from blood pressure level. In several studies, DCCB 
were not shown to reduce proteinuria levels and to slow 
the progression of CKD despite achieving BP goals compa-
rable to that achieved with angiotensin converting enzyme-
inhibitor (ACE-I) or angiotensin receptor blocker (ARB).36 
Results from animal studies suggested that DCCB markedly 
attenuate the autoregulatory ability of glomeruli.37,38 This 
would result in an increase in glomerular capillary pressure 
and albuminuria unless BP was reduced to level below 
120 mmHg.39 The result from our study may support this 
theory since the majority of study subjects did not have 
good BP control. Nevertheless, this association in our 
study only showed cross-sectional but not a cause-effect 
relationship.
It has been accepted that screening for microalbumin-
uria is cost-effectiveness in the prevention of progressive 
kidney disease in diabetic patients.40,41 However, there is 
still a debate concerning whether or not that benefit would 
be the same in other high risk groups such as hyperten-
sive patients. According to the 2007 European Society 
of Hypertension (ESH)/European Society of Cardiology 
(ESC) guidelines, microalbuminuria has been considered 
as a recommended test for risk stratification.9 However, 
this recommendation has not been implemented for 
hypertensive care in Thailand. Consequently, physicians 
and health care providers are still reluctant to screen 
for microalbuminuria and to follow this screening with 
  appropriate treatment in these populations. Atthobari et al 
have studied the issue of the cost-effectiveness of screening 
for albuminuria and the subsequent treatment of individuals 
with microalbuminuria with an ACE inhibitor. Although 
this approach was not cost-effective in terms of preventing 
end stage renal disease, it was cost-effective in prevent-
ing short term outcomes like cardiovascular events.42 
Our study reported the prevalence of microalbuminuria 
in nondiabetic hypertensive patients to be high enough 
to make screening worthwhile. Moreover, the screening 
method is easy and with an acceptable cost. Taking these 
evidences together with the Wilson-Jungner criteria for 
screening programs,43 we conclude that screening for albu-
minuria may prove to be useful in early risk assessment 
and prevention of cardiovascular disease in hypertensive 
patients in Thailand.
Our study has some limitations. Urinary albumin was 
measured on only a single occasion. Thus, we cannot 
exclude the possibility of false positive/negative test. Our 
study, however, corrected for some potential variability in 
urine concentrations by measuring for urinary creatinine 
excretion and used ACR in the analysis. Secondly, a cross-
sectional design limits the ability to show any cause-effect 
relationship between risk factors and albuminuria as well 
as cardiovascular and renal outcomes. Further longitu-
dinal studies of the natural course of microalbuminuria 
in nondiabetic hypertensive subjects will answer these 
questions.
Conclusion
In summary, microalbuminuria is not uncommon in Thai 
nondiabetic hypertensive subjects. Obesity and the use of 
dihydropyridine calcium channel blockers were found to 
be the important predictors. Prognostic value of the occur-
rence of microalbuminuria in this population remains to be 
  determined in prospective cohort studies.
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